Answers are grounded in this paper and cite their sources.
The pathogenic mechanism of preeclampsia involves endothelial dysfunction due to impaired angiogenesis, with an imbalance between pro-angiogenic and anti-angiogenic circulating factors. Angiogenesis occurs under both normal and pathological conditions and has an essential role in embryonic and placental development. One of the most important growth factors with a role in the regulation of angiogenesis is the Vascular Endothelial Growth Factor (VEGF), which exerts its function after binding to three receptors, VEGFR-1 (vascular endothelial growth factor receptor 1; flt-1), VEGFR-2 (vascular endothelial growth factor receptor 2; KDR) and VEGFR-3 (vascular endothelial growth factor receptor 3; flt-4). The binding of VEGF to the soluble form of VEGFR (sVEGFR or sflt-1) has an antiangiogenic effect. Preeclamptic placenta overexpresses sflt-1, which enters the maternal circulation, binds VEGF, and determines hypertension and proteinuria in the later stage of pregnancy. Sflt-1 levels could be used as a routine diagnostic test for preeclampsia, to differentiate preeclampsia from other diseases, and as a prognostic factor for imminent delivery in preeclamptic women. Also, sflt-1 could be a target for drug action in the treatment of preeclampsia.
No takes yet. Share an insight, caveat, or question.
Procopciuc et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: